Recently, clinical trials on the addition of a CDK4/6 inhibitor to the combination of fulvestrant and HER2-targeted therapy have been conducted in patients with HR + HER2+ breast cancer [13, 14]. This evidence concerns the gene ERBB2 and breast cancer.